Volume 5, Issue 8. In this podcast, Andrew J. Muir, MD from Duke University School of Medicine discusses the real-world data to support a sofosbuvir-ledipasvir treatment duration of 8 weeks versus 12 weeks, summarizes the current hepatitis C treatment options for patients with advanced kidney disease, and describes the risks and benefits of hepatitis C therapies in HIV-HCV coinfected patients. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter click here. The post Using Real World Data to Individualize HCV Management appeared first on DK ..read more

Volume 5, Issue 4. In this podcast Daryl T. Y. Lau, MD, MSc, MPH from Harvard Medical School discussed how to evaluate and mange patients who do not meet treatment criteria, the management of chronic hepatitis B during pregnancy, and how to identify patients appropriate for tenofovir alafenamide (TAF) therapy. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter click here. The post Clinical Approaches to HBV Therapy appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information ..read more

Volume 4, Issue 14. Drs Jordan Feld, MD, MPH and Joel Emery, HBSc, MD cover the important topic of Extrahepatic Manifestations of Hepatitis C: Screening and Management in the format of case-study scenarios for the clinical practice. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter click here. The post Extrahepatic Manifestations of Hepatitis C: Screening and Management appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information ..read more

Volume 4, Issue 10. Drs Kenneth Sherman, MD, PhD and Nadeem Anwar, MD cover the important topic of New Approaches to the Diagnosis and Management of Chronic HBV Infection in the format of case-study scenarios for the clinical practice. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter click here. The post New Approaches to the Diagnosis and Management of Chronic HBV Infection appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information ..read more

Volume 4, Issue 8, Part 3. Raymond T. Chung, MD from Harvard Medical School interviews Dr. David Wyles from the University of California San Diego about his presentation: Sofosbuvir/Velpatasivr Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study, presented at the April 2016 EASL meeting. The post Sofosbuvir/Velpatasvir fixed dose combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information ..read more

Take our post-test to claim CME credits. To listen to our full-length podcast, click here. Hosted on Acast. See acast.com/privacy for more information ..read more

Take our post-test to claim CME credits. To listen to our full-length podcast, click here. Hosted on Acast. See acast.com/privacy for more information ..read more

Volume 4, Issue 8, Part 1. Raymond T. Chung, MD from Harvard Medical School interviews Dr. Eric Lawitz from the University of Texas Health Science Center about his presentation: High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals presented at the April 2016 EASL meeting. The post High Efficacy of Sofosbuvir/Velpatasvir plus GS-9857 for 12 Weeks in Treatment-experienced Genotype 1-6 HCV-Infected Patients, Including those Previously Treated with Direct-actin ..read more

Take our post-test to claim CME credits. To listen to our full-length podcast, click here. Hosted on Acast. See acast.com/privacy for more information ..read more

Hepatitis B. It may not be curable yet, but as our knowledge continues to grow, so does our ability to benefit our patients today as we prepare them for tomorrow. That’s the focus of this Special HBV Edition of eViralHepatitis Review. The first part of this program presented an evidence-based expert commentary by eViralHepatitis Review Program Director Dr. Mark Sulkowski — Professor of Medicine at Johns Hopkins and Director of the Division of Infectious Diseases at Johns Hopkins Bayview Medical Center. This second part is an interview providing more in-depth discussions between Dr. S ..read more